Late-breaking EADV 2026 data support the use of DecisionDx-Melanoma in sentinel lymph node biopsy (SLNB) decision-making and in risk-aligned post-surgical management of cutaneous melanoma, according to a Morningstar-distributed release.

The headline of the late-breaking release states that the new data "support use of DecisionDx®-Melanoma in SLNB decision-making and risk-aligned post-surgical management." Specific endpoints, cohort size, hazard ratios, and discrimination metrics have not been disclosed at the headline level, and the full conference abstract and proceedings are the next opportunity for clinicians to examine the underlying numbers.

What does DecisionDx-Melanoma add to SLNB decisions?

Sentinel lymph node biopsy remains the standard nodal staging procedure for eligible melanoma patients whose tumors meet AJCC-defined thickness or ulceration thresholds. The procedure carries operative risk, and clinicians have long debated its therapeutic value in thin or intermediate-risk melanomas. A molecular test that stratifies a patient's pre-operative or peri-operative risk of nodal positivity could, in principle, guide which patients should be referred for the procedure and which can be observed.

The EADV 2026 late-breaking slot indicates that the new data extend the evidence base for using DecisionDx-Melanoma in that triage role, though specific performance characteristics against histopathologic or follow-up gold standards have not yet appeared in the headline-level announcement.

How would risk-aligned post-surgical care change practice?

Beyond nodal staging, the same late-breaking presentation addresses risk-aligned post-surgical management. Once a primary melanoma has been excised and nodal status clarified, surveillance intensity, imaging frequency, and adjuvant therapy referrals are typically calibrated to recurrence risk. Clinicians weigh AJCC stage, Breslow thickness, ulceration status, and patient factors when setting follow-up intervals.

The presentation frames DecisionDx-Melanoma as a tool for further refining that risk assignment, matching surveillance and adjuvant referrals to the biology of the tumor rather than to clinical staging alone. Again, the headline-level release does not specify the risk-class performance, net reclassification index, or absolute risk reductions associated with the test in this setting.

Why does the EADV late-breaking slot matter?

EADV late-breaking abstracts are reserved for analyses judged to carry immediate clinical relevance for the dermatology audience in Europe and globally. Selection in this category typically signals that the data have not previously been presented in full and that the meeting's scientific committee considers them practice-informing rather than confirmatory of prior work.

For DecisionDx-Melanoma, the late-breaking placement situates the assay alongside other molecular and clinicopathologic tools under active evaluation in melanoma prognostication, within an EADV 2026 program that also covers dermato-oncology updates, biologic therapies, and inflammatory skin disease.

What should clinicians watch for next?

The full EADV 2026 late-breaking data set, including any reported sensitivity, specificity, negative predictive value, and integration with AJCC staging, is expected to be detailed in the published conference abstract, in associated materials from the test developer, and in the conference proceedings once available. Clinicians following the DecisionDx-Melanoma evidence base should await the complete dataset before incorporating any updated thresholds into their SLNB referral pathways or post-surgical surveillance algorithms.